Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NKTR NASDAQ:URGN NASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNKTRNektar Therapeutics$55.62-7.8%$33.61$6.45▼$61.15$1.15B1.061.38 million shs960,433 shsURGNUrogen Pharma$17.26-4.1%$18.87$3.42▼$21.71$832.29M1.11.19 million shs919,437 shsVERVVerve Therapeutics$11.13$11.13$2.86▼$11.40$992.13M2.233.94 million shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNKTRNektar Therapeutics+1.22%+18.13%+122.29%+103.27%+232.40%URGNUrogen Pharma+0.62%-0.61%-2.76%+37.22%+37.75%VERVVerve Therapeutics0.00%0.00%0.00%-1.15%+124.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNKTRNektar Therapeutics$55.62-7.8%$33.61$6.45▼$61.15$1.15B1.061.38 million shs960,433 shsURGNUrogen Pharma$17.26-4.1%$18.87$3.42▼$21.71$832.29M1.11.19 million shs919,437 shsVERVVerve Therapeutics$11.13$11.13$2.86▼$11.40$992.13M2.233.94 million shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNKTRNektar Therapeutics+1.22%+18.13%+122.29%+103.27%+232.40%URGNUrogen Pharma+0.62%-0.61%-2.76%+37.22%+37.75%VERVVerve Therapeutics0.00%0.00%0.00%-1.15%+124.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNKTRNektar Therapeutics 2.86Moderate Buy$91.6764.81% UpsideURGNUrogen Pharma 3.00Buy$32.0085.40% UpsideVERVVerve Therapeutics 2.33Hold$14.5730.92% UpsideCurrent Analyst Ratings BreakdownLatest VERV, NKTR, and URGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/23/2025NKTRNektar TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$85.00 ➝ $105.009/19/2025NKTRNektar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.008/18/2025URGNUrogen PharmaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$36.008/11/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.008/5/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/8/2025NKTRNektar TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $85.007/8/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.007/7/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/27/2025VERVVerve TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$20.00 ➝ $13.506/26/2025VERVVerve TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 9/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNKTRNektar Therapeutics$98.43M10.75N/AN/A$4.94 per share11.26URGNUrogen Pharma$90.40M8.83N/AN/A($0.21) per share-82.19VERVVerve Therapeutics$32.33M30.69N/AN/A$5.83 per share1.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNKTRNektar Therapeutics-$118.96M-$8.80N/AN/AN/A-163.17%-631.43%-58.21%11/6/2025 (Estimated)URGNUrogen Pharma-$126.87M-$3.32N/AN/AN/A-164.44%-97,487.15%-59.38%11/5/2025 (Estimated)VERVVerve Therapeutics-$198.71M-$2.11N/AN/AN/A-303.64%-35.81%-27.57%N/ALatest VERV, NKTR, and URGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NKTRNektar Therapeutics-$3.13-$2.95+$0.18-$2.95$9.42 million$11.18 million8/7/2025Q2 2025URGNUrogen Pharma-$0.82-$1.05-$0.23-$1.05$23.06 million$24.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNKTRNektar TherapeuticsN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNKTRNektar TherapeuticsN/A2.612.61URGNUrogen PharmaN/A4.143.99VERVVerve TherapeuticsN/A9.849.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNKTRNektar Therapeutics75.88%URGNUrogen Pharma91.29%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipNKTRNektar Therapeutics5.25%URGNUrogen Pharma4.70%VERVVerve Therapeutics19.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNKTRNektar Therapeutics22019.02 million18.02 millionOptionableURGNUrogen Pharma20046.26 million44.09 millionOptionableVERVVerve Therapeutics11089.14 million71.94 millionOptionableVERV, NKTR, and URGN HeadlinesRecent News About These CompaniesWhy Intellia ($NTLA) Just Had A Major BreakoutSeptember 19, 2025 | msn.comEli Lilly's new $5B Virginia facility to target cancer, other illnessesSeptember 17, 2025 | msn.comEli Lilly's new $5B Virginia facility to target cancer, other drugsSeptember 16, 2025 | msn.comHectic Markets, Emotions Lead Biotechs To Tack On CVRsSeptember 10, 2025 | biospace.comBCanaccord Genuity Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)August 9, 2025 | theglobeandmail.comVerve Therapeutics Announces Merger and Nasdaq DelistingAugust 3, 2025 | theglobeandmail.comGene Therapy Companies Set Sights on Cardiovascular DiseaseAugust 1, 2025 | genengnews.comGVerve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102July 29, 2025 | msn.comEli Lilly and Company: Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskJuly 26, 2025 | finanznachrichten.deEli Lilly completes acquisition of Verve TherapeuticsJuly 25, 2025 | msn.comLilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskJuly 25, 2025 | prnewswire.comLilly and Verve announce expiration of Verve tender offerJuly 24, 2025 | prnewswire.comPenn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli LillyJuly 24, 2025 | msn.comEli Lilly Advances Pipeline and Gene Focus With Verve AcquisitionJuly 24, 2025 | finance.yahoo.com3 Bullish Biotech Stocks With Explosive Growth Trends...July 21, 2025 | marketbeat.comLilly’s $1 billion CRISPR bet: what Verve means for gene editingJuly 16, 2025 | thepharmaletter.comTGoldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)...July 15, 2025 | marketbeat.comBiotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.July 14, 2025 | msn.comBiotech Stocks Are Ready to Rebound. 3 to Watch Now.July 14, 2025 | msn.comTrump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.July 13, 2025 | hindustantimes.comHExperimental treatment for high cholesterol edits DNA in the body to reduce LDLJuly 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVERV, NKTR, and URGN Company DescriptionsNektar Therapeutics NASDAQ:NKTR$55.62 -4.71 (-7.81%) Closing price 04:00 PM EasternExtended Trading$55.94 +0.32 (+0.58%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Urogen Pharma NASDAQ:URGN$17.26 -0.73 (-4.06%) Closing price 04:00 PM EasternExtended Trading$17.25 -0.01 (-0.06%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Verve Therapeutics NASDAQ:VERVVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas It's a Good Time to Build a Position in KB Home Alphabet: Time to Take Profits, Buy, or Wait for a Pullback? Cintas Stock Sends a Clear Buy Signal as Momentum Builds Thor Industries Tracking for New Highs in 2026 Micron’s Stock Price Rally Is Not Over: MU $190 Is Coming Soon NuScale Power: The SMR Stock at the Heart of the AI Energy Boom Intel + NVIDIA: The Unexpected AI Alliance Shaking Wall Street Why Traders Are Doubling Down on SoundHound Stock After Big Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
